Alzamend Neuro Inc (ALZN)

[eqinvestor]

I have a question for anyone that can answer it. I am an extremely experienced healthcare industry investor. I've been investing for decades. Have been extremely successful in the healthcare sector. I was an early stage investor in immensely successful companies. I have always looked at it that a phase 1 company should be valued somewhere between 50 and 100 million. Phase 2 between 100 and 300. Of course, it also depends on what your indication is. A drug for arthritis would command a much higher market cap than a drug for toe fungus. Once you get in to phase 3 it could be 300 million on up. Right now with a market cap of 200 million, this company may be overvalued by a significant range. Why does anyone think this company is fairly valued at very early stage clinical trials. Admittedly, I don't know much about this company but have been following it based on the space that they are operating in.